The effect of vitamin D on the development and course of breast cancer (literature review)


  • M.V. Pavlushenko Bogomolets National Medical University, Kyiv, Ukraine
  • R.V. Lyubota Bogomolets National Medical University, Kyiv, Ukraine
  • O.S. Zotov Bogomolets National Medical University, Kyiv, Ukraine
  • M.F. Anikusko Kyiv City Clinical Oncology Center, Kyiv, Ukraine
  • R.I. Vereshchako Bogomolets National Medical University, Kyiv, Ukraine



breast cancer, vitamin D, risk factors, vitamin D receptors, review


Breast cancer is the most common cancer among the female population worldwide. The incidence of breast cancer is increasing every year. This requires the search for new trigger factors that can contribute to the onset and course of this disease. One of these factors is vitamin D, which is constantly deficient in most of the world’s population. This article provides a review of clinical studies over the last 15 years on the relationship between serum vitamin D concentration and breast cancer risk, prognostic factors, survival and treatment outcomes, and the effect of vitamin D receptor status on breast cancer. Studies have shown heterogeneity in research results that found the relationship between low vitamin D levels and breast cancer risk, prognostic factors and survival. There was no heterogeneity in studies showing an association between decreased vitamin D receptor status and worse prognosis. The situation was similar when studying the effect of vitamin D on impro­ving treatment outcomes. Despite conflicting research results, most studies show a correlation between vitamin D deficiency and breast cancer risk, prognostic factors, survival and treatment outcomes. Therefore, the selected vector of scientific researches is rational both from the point of view of eliminating the pandemic of vitamin D deficiency among the world’s population and preventing the spread of breast cancer.


Рак в Україні, 2018–2019: Бюлетень Національного канцер-реєстру № 21. Київ, 2020.

Lips P. Vitamin D physiology. Prog. Biophys. Mol. Biol. 2006 Sep. 92(1). 4-8.

Holick M.F. Vitamin D deficiency. N. Engl. J. Med. 2007. 357. 266-281.

Shao T., Klein P., Grossbard M.L. Vitamin D and Breast Cancer. Oncologist. 2012 Jan. 17(1). 36-45.

Feldman D., Krishnan A.V., Swami S., Giovannucci E., Feldman B.J. The role of vitamin D in reducing cancer risk and progression. Nat. Rev. Cancer. 2014. 14(5). 342-357.

Welsh J. Function of the vitamin D endocrine system in mammary gland and breast cancer. Mol. Cell. Endocrinol. 2017. 453. 88-95.

Mohr S.B., Gorham E.D., Kim J., Hofflich H., Garland C.F. Meta-analysis of vitamin D sufficiency for improving survival of patients with breast cancer. Anticancer Res. 2014. 34(3). 1163-1166.

Bikle D. Nonclassic actions of vitamin D. J. Clin. Endocrinol. Metab. 2009. 94. 26-34.

Hobaus J., Thiem U., Hummel D.M., Kallay E. Role of calcium, vitamin D, and the extrarenal vitamin D hydroxylases in carcinogenesis. Anti-cancer Agents Med. Chem. 2013. 13. 20-35.

Alipour S., Hadji M., Hosseini L., Omranipour R., Saberi A., Seifollahi A., Bayani L., Shirzad N. Levels of serum 25-hydroxy-vitamin d in benign and malignant breast masses. Asian Pac. J. Cancer Prev. 2014. 15(1). 129-32.

Kim Y., Je Y. Vitamin D intake, blood 25(OH)D levels, and breast cancer risk or mortality: a meta-analysis. Br. J. Cancer. 2014. 110(11). 2772-2784.

Chen P., Li M., Gu X., Liu Y., Li X. et al. Higher Blood 25(OH)D Level May Reduce the Breast Cancer Risk: Evidence from a Chinese Population Based Case-Control Study and Meta-Analysis of the Observational Studies. PLoS ONE. 2013. 8(1). e49312.

Mohr S.B., Gorham E.D., Alcaraz J.E. et al. Serum 25-hydroxyvitamin D and prevention of breast cancer: pooled analysis. Anticancer Res. 2011. 31. 2939-48.

Kim Y., Franke A.A., Shvetsov Y.B., Wilkens L.R., Cooney R.V., Lurie G., Maskarinec G., Hernandez B.Y., Le Mar­chand L., Henderson B.E. et al. Plasma 25-hydroxyvitamin D3 is associated with decreased risk of postmenopausal breast cancer in whites: A nested case-control study in the multiethnic cohort study. BMC Cancer. 2014. 14. 29.

Kuhn T., Kaaks R., Becker S., Eomois P.P., Clavel-Chapelon F., Kvaskoff M. et al. Plasma 25-hydroxyvitamin D and the risk of breast cancer in the European prospective investigation into cancer and nutrition: a nested case-control study. Int. J. Cancer. 2013. 133. 1689-1700.

Eliassen A.H., Spiegelman D., Hollis B.W., Horst R.L., Willett W.C., Hankinson S.E. Plasma 25-hydroxyvitamin D and risk of breast cancer in the Nurses’ Health Study II. Breast Cancer Res. 2011. 13. R50.

Lopes N., Paredes J., Costa J.L., Ylstra B., Schmitt F. Vitamin D and the mammary gland: a review on its role in normal development and breast cancer. Breast Cancer Res. 2012. 14. 211.

Shamsi U., Khan S., Azam I., Habib Khan A., Maqbool A., Hanif M., Gill T., Iqbal R., Callen D. A multicenter case control study of association of vitamin D with breast cancer among women in Karachi, Pakistan. PLoS One. 2020 Jan 22. 15(1). e0225402.

Estébanez N., Gómez-Acebo I., Palazuelos C. et al. Vitamin D exposure and Risk of Breast Cancer: a meta-analysis. Sci Rep. 2018. 8. 9039.

Yao S., Kwan M.L., Ergas I.J., Roh J.M., Cheng T.D., Hong C.C., McCann S.E., Tang L., Davis W., Liu S. et al. Association of serum level of vitamin D at diagnosis with breast cancer survival: a case-cohort analysis in the pathways study. JAMA Oncol. 2017. 3(3). 351-7.

Janbabai G., Shekarriz R., Hassanzadeh H., Aarabi M., Borhani S.S. A survey on the relationship between serum 25-hydroxy vitamin D level and tumor characteristics in patients with breast cancer. Int. J. Hematol. Oncol. Stem Cell Res. 2016. 10. 30-36.

Hatse S., Lambrechts D., Verstuy A. et al. Vitamin D status at breast cancer diagnosis: correlation with tumor characteristics, disease outcome, and genetic determinants of vitamin D insufficiency. Carcinogenesis. 2012. 33(7). 1319-1326.

Yao S., Sucheston L.E., Millen A.E., Johnson C.S., Trump D.L., Nesline M.K. et al. Pretreatment serum concentrations of 25-hydroxyvitamin D and breast cancer prognostic characteristics: a case-control and a case-series study. PLoS One. 2011 Feb. 28. 6(2). e17251.

De Sousa Almeida-Filho B., De Luca Vespoli H., Pessoa E.C., Machado M., Nahas-Neto J. Vitamin D deficiency is associated with poor breast cancer prognostic features in postmenopausal women. EAP. J. Steroid Biochem. Mol Biol. 2017 Nov. 174. 284-289.

Imtiaz S., Siddiqui N., Raza S.A. et al. Vitamin D deficiency in newly diagnosed breast cancer patients. Indian J. Endocr. Metab. 2012. 16. 409-13.

Peppone L., Rickles A., Huston A., Sprod L., Hicks D., Mustian K., Skinner K. The association between prognostic demographic and tumor characteristics of breast carcinomas with serum 25-OH vitamin D levels. Cancer Epidemiol. Biomarkers Prev. 2011. 20. 717.

Rainville C., Khan Y., Tisman G. Triple negative breast cancer patients presenting with low serum vitamin D levels: a case series. Cases J. 2009. 2. 8390.

Huss L., Butt S.T., Borgquist S., Elebro K., Sandsveden M., Rosendahl A., Manjer J. Vitamin D receptor expression in invasive breast tumors and breast cancer survival. Breast Cancer Res. 2019. 21. 84.

Al-Azhri J., Zhang Y., Bshara W., Zirpoli G.R., McCann S.E., Khoury T., Morrison C.D., Edge S.B., Ambrosone C.B., Yao S. Tumor expression of vitamin D receptor and breast cancer histopathological characteristics and prognosis. Clin. Cancer Res. 2017. 23(1). 97-103.

Lopes N., Sousa B., Martins D., Gomes M., Vieira D., Veronese L.A. et al. Alterations in Vitamin D signalling and metabolic pathways in breast cancer progression: A study of VDR, CYP27B1 and CYP24A1 expression in benign and malignant breast lesions. BMC Cancer. 2010. 10. 483.

Zati Zehni A., Jacob S.N., Mumm J.N., Heidegger H.H., Ditsch N., Mahner S. et al. Hormone Receptor Expression in Multicentric/Multifocal versus Unifocal Breast Cancer: Especially the VDR Determines the Outcome Related to Focality. Int. J. Mol. Sci. 2019. 20(22).

Chen S. Aromatase and breast cancer. Front Biosci. 1998. 3. d922-33.

Krishnan A.V., Swami S., Feldman D. The Potential Therapeutic Benefits of Vitamin D in the Treatment of Estrogen Receptor Positive Breast Cancer. Steroids. 2012. 77(11). 1107-12.

Khan Q.J., Reddy P.S., Kimler B.F. et al. Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer. Breast Cancer Res. Treat. 2010. 119. 111-118.

Prieto-Alhambra D., Javaid M.K., Servitja S., Arden N.K., Martinez-García M., Diez-Perez A., Albanell J., Tusquets I., Nogues X. Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: a prospective cohort study. Breast Cancer Res. Treat. 2011. 125. 869-78.

Amir E., Simmons C.E., Freedman O.C., Dranitsaris G., Cole D.E., Vieth R., Ooi W.S., Clemons M. A phase 2 trial exploring the effects of high dose (10, 000 IU/day) vitamin D(3) in breast patients with bone metastases. Cancer. 2010. 116(2). 184-191.

Coleman R.E. Bisphosphonates: clinical experience. Oncologist. 2004. 9 Suppl 4. 14-27.

Tanaka M., Itoh S., Takeuchi Y. Effectiveness of bisphosphonate combined with activated vitamin D in patients with aromatase inhibitor-induced osteoporosis after breast cancer operation. Osteoporos. Sarcopenia. 2018 Sep. 4(3). 102-108.

Charehbili A., Hamdy N.A., Smit V.T., Kessels L., van Bochove A., van Laarhoven H.W., Putter H., Meershoek-Klein Kranenbarg E., van Leeuwen-Stok A.E., van der Hoeven J.J., van de Velde C.J., Nortier J.W., Kroep J.R. Vitamin D (25-ОH D3) status and pathological response to neoadjuvant chemotherapy in stage II/III breast cancer: Data from the NEOZOTAC trial (BOOG 10-01). Dutch Breast Cancer Research Group (BOOG).

Maalmi H., Ordonez-Mena J.M., Schottker B., Brenner H. Serum 25-hydroxyvitamin D levels and survival in colorectal and breast cancer patients: systematic review and meta-analysis of prospective cohort studies. Eur. J. Cancer. 2014. 50. 1510-1521.

Goodwin P.J. et al. Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. J. Clin. Oncol. 2009. 27. 3757-3763.

Thanasitthichai S., Prasitthipayong A., Boonmark K., Purisa W., Guayraksa K. Negative Impact of 25-hydroxyvitamin D Deficiency on Breast Cancer Survival. Asian Pac. J. Cancer Prev. 2019 Oct 1. 20(10). 3101-3106.

Lim S.T., Jeon Y.W., Suh Y.J. Association between alterations in the serum 25-hydroxyvitamin d status during follow-up and breast cancer patient prognosis. Asian Pac. J. Cancer Prev. 2015. 16(6). 2507-13.

Ismail A., El-Awady R., Mohamed G., Hussein M., Ramadan S.S. Prognostic Significance of Serum Vitamin D Levels in Egyptian Females with Breast Cancer. Asian Pac. J. Cancer Prev. 2018 Feb 26. 19(2). 571-576.

Vrieling A., Seibold P., Johnson T.S. et al. Circulating 25-hydroxyvitamin D and postmenopausal breast cancer survival: Influence of tumor characteristics and lifestyle factors? Int. J. Cancer. 2014. 134. 2972-83.